Guidance Recap Podcast | Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biologics
FDA Guidance Recap PodcastShow Notes
Dr. Dan Rubin, statistician, Division of Biometrics IV in CDER’s Office of Biostatistics sharing some thoughts draft guidance Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biologics
More from FDA Guidance Recap Podcast
Jul 7, 2026
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Jun 22, 2026
Guidance Recap Podcast | Master Protocols for Drug and Biological Product Development
Mar 25, 2026
Guidance Recap Podcast | Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
Oct 22, 2025
Guidance Recap Podcast: Selecting, Developing or Modifying Fit-for-Purpose Clinical Outcomes Assessments
Oct 16, 2024
Guidance Recap Podcast | Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development